Ulrich Granzer

Portrait Name

Ulrich Granzer, Ph.D., the founder of Granzer Regulatory Consulting & Services, graduated as a pharmacist in 1984 from the University of Marburg, followed by PhD studies during which he also acted as lecturer for pharmaceutical chemistry. In 1988 he served in the German Air Force and advanced to the rank of a captain with responsibility for drug safety.

In 1989, Ulrich Granzer started his industry career in the Regulatory Affairs department at Glaxo. In 1993 he was appointed Director of Regulatory Affairs. Thereafter, he served as a member of Glaxo's and then Glaxo Wellcome's Global Regulatory Board. During this time he was also the project leader for a company-wide re-engineering at Glaxo Germany.

In 1998 Ulrich Granzer joined BASF Pharma as Vice President of Global Regulatory Centres, assuming global responsibility for Regulatory Affairs, Drug Safety, and GXP in drug development.

At Knoll he was responsible for the development of small molecules as well as several biological compounds in the indications of stroke, septic shock, and rheumatoid arthritis. He was instrumental in the program for the first fully human anti TNF antibody, now marketed as Humira.

After Knoll was taken over by Abbott, he joined Bayer as Vice President Global Regulatory Affairs with the responsibility for all regulatory aspects of development and submission projects worldwide.

At the beginning of 2002 Ulrich Granzer decided to start his own business and founded Granzer Regulatory Consulting & Services. The company has since steadily grown and today employs 25 highly experienced consultants committed to provide you with high quality services.